PLOD1 and nonpapillary renal cell carcinoma: Elevated PLOD expression shows promise as a prognostic biomarker in ccRCC, adding complementary value to existing models like IMDC or SSIGN by capturing ECM remodeling and fibrosis levels not reflected in current clinical parameters.